Neurol. praxi. 2024;25(6):492-495 | DOI: 10.36290/neu.2024.074
Ponesimod as a suitable high-efficacy treatment for multiple sclerosis
- Lékařská fakulta Univerzity Palackého v Olomouci
- Neurologická klinika Fakultní nemocnice Olomouc
This case report describes the treatment of a patient with relapsing-remitting multiple sclerosis (RR-RS) who also suffers from Crohn's disease. After initial therapy with glatiramer acetate and interferon beta-1a, the patient had ongoing disease activity that required a change in treatment. Considering the need for highly effective therapy and the patient's preference for less frequent visits to the medical facility, treatment with ponesimod was started in April 2022. After more than two years of treatment, the patient remains clinically stable, without new relapses or disease progression, and Crohn's disease is in remission. The patient tolerates the treatment well and leads a full life, which confirms the efficacy and safety of ponesimod as a suitable choice for patients with active MS and comorbidities.
Keywords: ponesimod, multiple sclerosis, efficacy, safety, Crohn's disease.
Received: October 15, 2024; Revised: November 11, 2024; Accepted: November 11, 2024; Prepublished online: November 11, 2024; Published: December 31, 2024 Show citation
PDF will be unlocked 31.12.2025 |
References
- Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate receptor Modulator therapy for Multiple sclerosis: Differential downstream receptor signalling and clinical profile Effects. Drugs. 2020;81(2):207-231. https://doi.org/10.1007/s40265-020-01431-8.
Go to original source... 
Go to PubMed... - Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7. PMID: 18970977. Go to original source... Go to PubMed...
- Coyle PK, Freedman MS, Cohen BA, et al. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review. Annals of Clinical and Translational Neurology. 2024;11(4):842-855. https://doi.org/10.1002/acn3.52017. Go to original source... Go to PubMed...
- Goris A, Vandebergh M, McCauley JL, et al. Genetics of multiple sclerosis: lessons from polygenicity. The Lancet Neurology. 2022;21(9):830-842. https://doi.org/10.1016/s1474-4422(22)00255-1. Go to original source... Go to PubMed...
- Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the Active-Comparator Phase 3 OPTIMUM study. JAMA Neurology. 2021;78(5):558. https://doi.org/10.1001/jamaneurol.2021.0405. Go to original source... Go to PubMed...
- Pérez-Jeldres, T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate signaling in Immune-Mediated Diseases: Beyond Multiple sclerosis. Drugs. 2021;81(9):985-1002. https://doi.org/10.1007/s40265-021-01528-8. Go to original source... Go to PubMed...
- Peterka M, Potužník P. Sphingosine-1-phosphate receptor modulators in the treatment of early phase multiple sclerosis. Neurol. praxi. 2023;24(5):360-366. https://doi.org/10.36290/neu.2023.064. Go to original source...
- Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate receptor modulators for multiple sclerosis. CNS Drugs. 2021;35(4):385-402. https://doi.org/10.1007/s40263-021-00798-w. Go to original source... Go to PubMed...
- Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11. PMID: 33174475; PMCID: PMC7720355. Go to original source... Go to PubMed...
- Wiendl H, Hauser S, Nicholas J, et al. Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010). Neurology. 2024;102(17_supplement_1). https://doi.org/10.1212/wnl.0000000000205570. Go to original source...